R1 RCM (NASDAQ:RCM) Price target lowered to $28.00 at Deutsche Bank Aktiengesellschaft
R1 RCM (NASDAQ:RCM – Get Valuation) had its price target reduced by Deutsche Bank Aktiengesellschaft from $30.00 to $28.00 in a research note published on Tuesday morning, reports The Fly.
A number of other analysts have also recently commented on RCM. Robert W. Baird raised his price target on R1 RCM from $29.00 to $32.00 in a Thursday, March 3 research report. Guggenheim assumed coverage on R1 RCM in a Wednesday, April 13 research report. They issued a neutral rating on the title. Finally, Zacks Investment Research upgraded R1 RCM from a hold rating to a buy rating and set a price target of $30.00 on the stock in a Thursday, April 21 research report. One equity research analyst gave the stock a hold rating and nine gave the stock a buy rating. According to data from MarketBeat.com, the stock has a consensus buy rating and an average target price of $29.25.
NASDAQ:RCM shares opened at $19.11 on Tuesday. The company has a current ratio of 1.43, a quick ratio of 1.43 and a debt ratio of 2.19. R1 RCM has a 12 month low of $18.71 and a 12 month high of $27.86. The stock has a market capitalization of $5.32 billion, a P/E ratio of -8.89, a P/E/G ratio of 2.46 and a beta of 0.86. The company has a 50-day moving average of $25.25 and a 200-day moving average of $24.55.
R1 RCM (NASDAQ:RCM – Get Rating) last released its quarterly results on Monday, May 9. The healthcare provider reported EPS of $0.09 for the quarter, missing analyst consensus estimates of $0.13 per ($0.04). R1 RCM had a net margin of 6.59% and a return on equity of 30.22%. The company posted revenue of $385.70 million for the quarter, versus a consensus estimate of $384.18 million. In the same quarter of the previous year, the company had earned earnings per share ($2.37). The company’s quarterly revenue increased by 12.6% compared to the same quarter last year. On average, stock analysts expect R1 RCM to post 0.46 earnings per share for the current fiscal year.
A number of institutional investors and hedge funds have recently changed their positions in RCM. PNC Financial Services Group Inc. increased its stake in R1 RCM shares by 89.5% in Q3. PNC Financial Services Group Inc. now owns 4,953 shares of the healthcare provider worth $109,000 after buying 2,339 additional shares last quarter. Advisor Group Holdings Inc. increased its holdings in R1 RCM by 8.3% in Q3. Advisor Group Holdings Inc. now owns 5,723 shares of the healthcare provider worth $128,000 after purchasing an additional 439 shares during the period. Los Angeles Capital Management LLC bought a new position in R1 RCM in Q3 worth $811,000. The Swiss National Bank increased its holdings in R1 RCM by 0.6% in the third quarter. The Swiss National Bank now owns 260,500 shares of the healthcare provider worth $5,734,000 after buying an additional 1,500 shares during the period. Finally, CIBC Asset Management Inc. increased its stake in R1 RCM by 11.8% in the third quarter. CIBC Asset Management Inc. now owns 10,689 shares of the healthcare provider worth $235,000 after purchasing an additional 1,131 shares during the period. Institutional investors and hedge funds own 41.97% of the company’s shares.
R1 RCM Company Profile (Get a rating)
R1 RCM Inc provides Revenue Cycle Management (RCM) for healthcare providers in the United States. The company offers end-to-end RCM services to manage their revenue cycle operations which encompass patient registration, insurance and benefit verification, medical treatment documentation and coding, invoice preparation and collections. with patients and payers.
Get news and reviews for R1 RCM Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for R1 RCM and related companies with MarketBeat.com’s free daily email newsletter.